McKesson Corporation (MCK) Return on Invested Capital (ROIC): 31.48%
Is McKesson Corporation’s return on invested capital (ROIC) high or low?
McKesson Corporation's return on invested capital (ROIC) of 31.48% is 52% above its 5-year average of 20.68%, near the high end of its 5-year range (11.46%–31.48%).
As of Friday, June 19, 2026. 14.93% above its 12-month average of 27.39%.
MCK Return on Invested Capital (ROIC) Chart
MCK Average Return on Invested Capital (ROIC) Chart
MCK Current vs Average Return on Invested Capital (ROIC) Chart
MCK Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
31.48%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
27.39%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
24.73%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
20.68%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
16.67%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
13.87%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
11.64%
CURRENT VS TTM AVG
+14.93%
CURRENT VS 3Y AVG
+27.29%
CURRENT VS 5Y AVG
+52.20%
CURRENT VS 10Y AVG
+88.87%
CURRENT VS 15Y AVG
+126.92%
CURRENT VS 20Y AVG
+170.49%
MCK Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| McKesson Corporation (MCK) | $87.88B | 31.48% | 27.39% | 24.73% | 20.68% |
| Elevance Health Inc. (ELV)vs › | $84.37B | 6.65% | 6.70% | 7.11% | 7.33% |
| HCA Healthcare, Inc. (HCA)vs › | $83.23B | 18.53% | 17.61% | 17.07% | 16.89% |
| Medtronic plc (MDT)vs › | $101.86B | 6.13% | 6.11% | 5.46% | 5.53% |
| Cigna Corporation (CI)vs › | $73.88B | 7.35% | 7.02% | 7.07% | 6.50% |
| Boston Scientific Corporation (BSX)vs › | $67.35B | 8.78% | 7.46% | 6.12% | 5.55% |
| Bristol-Myers Squibb Company (BMY)vs › | $110.27B | 13.90% | 13.75% | 11.92% | 10.17% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $62.84B | 8.51% | 9.70% | 12.91% | 18.22% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $114.63B | 18.12% | 10.38% | 14.75% | 17.51% |
| Stryker Corporation (SYK)vs › | $119.03B | 8.53% | 10.14% | 10.34% | 10.08% |
Capital Efficiency
ROIC
31.5%
ROE
-219.2%
McKesson Corporation Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
McKesson Corporation Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for McKesson Corporation (MCK)?
- The return on invested capital (ROIC) for MCK stock is 31.48%.
- Is McKesson Corporation's return on invested capital (ROIC) high or low?
- McKesson Corporation's return on invested capital (ROIC) of 31.48% is 52% above its 5-year average of 20.68%, near the high end of its 5-year range (11.46%–31.48%).
- What is the TTM average return on invested capital (ROIC) for McKesson Corporation (MCK)?
- The TTM average return on invested capital (ROIC) for MCK stock is 27.39%.
- What is the 3Y average return on invested capital (ROIC) for McKesson Corporation (MCK)?
- The 3Y average return on invested capital (ROIC) for MCK stock is 24.73%.
- What is the 5Y average return on invested capital (ROIC) for McKesson Corporation (MCK)?
- The 5Y average return on invested capital (ROIC) for MCK stock is 20.68%.
- What is the 10Y average return on invested capital (ROIC) for McKesson Corporation (MCK)?
- The 10Y average return on invested capital (ROIC) for MCK stock is 16.67%.
- What is the 15Y average return on invested capital (ROIC) for McKesson Corporation (MCK)?
- The 15Y average return on invested capital (ROIC) for MCK stock is 13.87%.
- What is the 20Y average return on invested capital (ROIC) for McKesson Corporation (MCK)?
- The 20Y average return on invested capital (ROIC) for MCK stock is 11.64%.
McKesson Corporation Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-03-31 | 31.48% |
| 2025-03-31 | 23.30% |
| 2024-03-31 | 21.22% |
| 2023-03-31 | 22.92% |
| 2022-03-31 | 11.46% |
| 2021-03-31 | 13.72% |
| 2020-03-31 | 14.80% |
| 2019-03-31 | 5.73% |
| 2018-03-31 | 13.50% |
| 2017-03-31 | 10.86% |
| 2016-03-31 | 14.35% |
| 2015-03-31 | 11.11% |
| 2014-03-31 | 7.22% |
| 2013-03-31 | 12.24% |
| 2012-03-31 | 14.13% |
| 2011-03-31 | 11.53% |
| 2010-03-31 | 12.18% |
| 2009-03-31 | 13.48% |
| 2008-03-31 | 10.84% |
| 2007-03-31 | 10.68% |
| 2006-03-31 | 10.02% |
| 2005-03-31 | 9.50% |
| 2004-03-31 | 9.88% |
| 2003-03-31 | 9.56% |
| 2002-03-31 | 8.22% |
| 2001-03-31 | -8.29% |
| 2000-03-31 | 1.81% |
| 1999-03-31 | 3.11% |
| 1998-03-31 | 6.45% |
| 1997-03-31 | 0.45% |
Related Metrics
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler